RE: CEL,14 Jan 2025 20:32
In October 2024, Celadon announced a five-year sales contract with a newly established healthcare company for the supply of medicinal cannabis products from its UK facility.
The contract includes minimum order quantities valued up to £10.5 million over the term, with volumes increasing significantly from the first to the third year.
Cultivation for the initial supply is set to begin within 12 months of signing. This agreement elevates Celadon’s potential order book to approximately £40.7 million, combining previous contracts, including a £26 million European deal announced in November 2023. The company’s recent collaboration with Denmark’s Valeos Pharma A/S enhances its capacity to meet growing demand for high-quality, pharmaceutical-grade medicinal cannabis across Europe.